US OptionsDetailed Quotes
ATHA241220P500
- 0.00
- 0.000.00%
15min DelayClose Dec 20 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest0.50Strike Price0.00Turnover0.00%IV13.19%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.58Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Athira Stock Discussion
Sign in to post a comment
$MSP Recovery (LIFW.US)$ Ticker change to MSPR Monday to consolidate services. Even with negative profit margin, of note, company had $10M settlements from property and casualty insurers and acquired Medicare claims valued $10.6B. Low float. Currently trading above 10/20 EMA suggesting short term bullishness. SI 162%, 0 shares LTB
$Roth CH Acquisition V Co(Delisted) (ROCL.US)$ Ticker change tomorr...
$Roth CH Acquisition V Co(Delisted) (ROCL.US)$ Ticker change tomorr...
51
25
6
$Athira (ATHA.US)$
This is their balance sheet as of SEP 2024, in this it shows stock holders equity 57Mil, which is now down to 25M(Market cap), so the liability is 25+28=53Mil which is still less than the cash they hold 69Mil...
This is their balance sheet as of SEP 2024, in this it shows stock holders equity 57Mil, which is now down to 25M(Market cap), so the liability is 25+28=53Mil which is still less than the cash they hold 69Mil...
1
$Athira (ATHA.US)$
someone new something 👀
someone new something 👀
3
2
$Athira (ATHA.US)$
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND
Friday, 6th December at 5:30 pm
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highli...
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND
Friday, 6th December at 5:30 pm
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highli...
1
2
$Athira (ATHA.US)$ Why is it going up so slowly? Is it we are waiting for a bigger news?
1
1
$Athira (ATHA.US)$ no downside they closed down that failing company months ago false news been working out of their new lab for almost a year now and with AI about to cut workforce cost we will see more profits 📈 😉
3
3
No comment yet
凑仔公阿当 : I hope so